Advertisement
Advertisement
ZVRA
Zevra Therapeutics, Inc. Common Stock
11.59
USDSponsored
+1.06
+10.07%
Nov 06, 15:59 UTC -5
Closed
After-Market
11.47
-0.12
-1.00%
Zevra Therapeutics, Inc. Common Stock (ZVRA) Earnings
ZVRA Earnings Reports
Positive Surprise Ratio
ZVRA beat 23 of 44 last estimates.
52%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$40.36M
/$0.18
Implied change from Q3 26 (Revenue/ EPS)
+6.88%
/--
Implied change from Q4 25 (Revenue/ EPS)
+18.26%
/-14.29%
Zevra Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 03, 2026, ZVRA reported earnings of 0.18 USD per share (EPS) for Q3 26, beating the estimate of 0.15 USD, resulting in a 12.64% surprise. Revenue reached 37.76 million, compared to an expected 37.82 million, with a -0.16% difference. The market reacted with a +8.87% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.18 USD, with revenue projected to reach 40.36 million USD, implying an increase of 0.00% EPS, and increase of 6.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.02
Actual
$0.06
Surprise
+144.90%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.89
Actual
$1.96
Surprise
+3.17%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.32
Actual
$0.36
Surprise
+9.16%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.36
Surprise
-11.15%
Profound Medical Corp. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.18
Actual
-$0.21
Surprise
-11.41%
Akebia Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.03
Actual
-$0.04
Surprise
-6.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
FAQ
What were Zevra Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Zevra Therapeutics, Inc. Common Stock reported EPS of $0.18, beating estimates by 12.64%, and revenue of $37.76M, -0.16% below expectations.
How did the market react to Zevra Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 8.87%, changed from $10.26 before the earnings release to $11.17 the day after.
When is Zevra Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for Zevra Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Zevra Therapeutics, Inc. Common Stock is expected to report EPS of $0.18 and revenue of $40.36M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.